Here are five notes from the recommendations:
- The update includes refinement of definitions, reporting terms and grading for cardiovascular adverse events.
- Event adjudication is recommended for complex or rare cardiovascular events such as myocarditis to improve accuracy in classification.
- Trial sites should be educated on recognizing and correctly reporting cardiovascular events. Baseline tests should be used to identify potential adverse events earlier.
- Data collection should be standardized to ensure consistent reporting across trial sites and promote accurate assessment of clinical outcomes.
- Trial sites are encouraged to collaborate with cardiologists as evidence of cancer therapies’ effect on cardiovascular health grows.
Read the full recommendations here.
Leave a Reply